DNA Nanocarriers for Systemic Administration: Characterization and In Vivo Bioimaging in Healthy Mice

David, Stéphanie; Passirani, Catherine; Carmoy, Nathalie; Mével, Mathieu; Chatin, Benoît; Benoı̂t, Jean-Pierre; Montier, Tristan; Pitard, Bruno

doi:10.1038/mtna.2012.56

Cited by 21 publications

(24 citation statements)

References 36 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PEG DNA LNCs (Lipid NanoCapsules) showed a rapid clearance, probably due to rapid blood clearance after the second administration. This difference observed in terms of bloodstream circulation and distribution profiles can be explained by the lipid and surface composition of the molecules tested [42]. Considering the intracellular pathways followed by the two cationic lipids, BGTC and DOSP identify two distinct escape mechanisms from endosomes.…”

Section: The Development Of Lipids Derived From Cholesterol For Use Imentioning

confidence: 96%

“…DNA MMS DOSP exhibited an extended blood circulation, highlighted by a significant and visible accumulation for up to 24 h following the first injection, with fluorescence intensities four to five times greater than DNA MMS GAL [42]. Grafting a galactosylated motif to the formulations leads to their concentration in the liver [42]. As seen previously, this phenomenon is due to the binding of a galactose motif to the asialoglycoprotein receptor (ASGP-R), located on hepatocytes that interact with terminal GAL-bearing ASGP, and promotes specific internalization of GAL-containing systems [159,160].…”

Section: Biodistribution and Elimination Of Synthetic Vectorsmentioning

confidence: 98%

“…DNA MMS DOSP had a lower concentration in the liver compared to DNA MMS BGTC. DNA MMS DOSP exhibited an extended blood circulation, highlighted by a significant and visible accumulation for up to 24 h following the first injection, with fluorescence intensities four to five times greater than DNA MMS GAL [42]. Grafting a galactosylated motif to the formulations leads to their concentration in the liver [42].…”

Section: Biodistribution and Elimination Of Synthetic Vectorsmentioning

confidence: 98%

“…For the largest delivery systems (50-250 nm), their degradation was limited by their size, increasing their half-life in the bloodstream [129,155,158]. Another study comparing the biodistribution of several NA nanocarriers composed of new multimodular systems (MMS) with different cationic compounds, such as dioleylaminesuccinylparomomycin (DNA MMS DOSP), or bis(guanidinium)-tren-cholesterol (DNA MMS BGTC), and/or DNA lipid nanocapsules (DNA LNCs), revealed various biodistribution profiles and circulation times according to the cationic carrier employed, and its composition and surface properties [42]. For example, after intravenous injection, the authors reported that DNA MMS BGTC was rapidly accumulated in the liver of healthy mice.…”

Section: Biodistribution and Elimination Of Synthetic Vectorsmentioning

confidence: 99%

“…In order to develop more effective synthetic delivery systems, original multimodular systems (MMS) based on DOSP or BGTC have been synthesized and assessed in cell lines and animal models [42]. When, two intravenous administrations were performed, DOSP complexes showed identical best and prolonged biodistribution in the bloodstream with no significant cytotoxicity after the second injection.…”

Section: The Development Of Lipids Derived From Cholesterol For Use Imentioning

confidence: 99%

See 4 more Smart Citations

Synthetic vectors for gene delivery: An overview of their evolution depending on routes of administration.

Belmadi

Midoux

Loyer

et al. 2015

Biotechnology Journal

Self Cite

View full text Add to dashboard Cite

Nucleic acid delivery constitutes an emerging therapeutic strategy to cure various human pathologies. This therapy consists of introducing genetic material into the whole body or isolated cells to correct a cellular abnormality or disfunction. As with any drug, the main objective of nucleic acid delivery is to establish optimal balance between efficacy and tolerance. The methods of administration and the vectors used are selected depending on whether the goal of treatment is the production of an active protein; the replacement of a missing or inactive gene; or the combat of acquired diseases, such as cancer or AIDS. In that sense, synthetic vectors represent a valuable solution because they are well characterized, their structure can be fine tuned, and their potential toxicity can be reduced, since toxicity depends on the composition of the formulations. Here we review various synthetic vectors for gene delivery and address the question of their biodistribution as a function of the route of administration. We highlight the modifications to vectors structure and formulations necessary to overcome the major hurdles limiting the effectiveness of nucleic acid therapies.

show abstract

Section: The Development Of Lipids Derived From Cholesterol For Use Imentioning

confidence: 96%